Propanc Biopharma, Inc.

PPCB

US74346N8002

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 19/05/2026			5-day change	1st Jan Change
2.005 ^USD	-2.20%		-11.38%	-85.05%

01:59pm	Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients	RE
05-14	Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI

Propanc Biopharma Inc - files to offer resale of up to 15 million shares of common stock by selling stockholder - SEC filing

Published on 04/10/2026 at 10:34 pm BST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Propanc Biopharma, Inc.

01:59pm	Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients	RE
05-14	Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-14	Propanc Biopharma implements reverse stock split to support continued Nasdaq listing and growth plans	RE
04-10	Propanc Biopharma Inc - files to offer resale of up to 15 million shares of common stock by selling stockholder - SEC filing	RE
03-24	Propanc Biopharma Inc Establishes Multi-Year Joint Research Collaboration Agreement with the Universities of Jaén and Granada Spain	CI
03-12	Propanc Biopharma, Inc. Targets Pancreatic Cancer Market With PRP Proenzyme Therapy	CI
03-03	Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models	RE
03-03	Propanc Biopharma, Inc. Highlights Lead Asset PRP As Novel Therapeutic Approach For Metastatic Cancer	CI
02-26	Propanc Biopharma, Inc. Announces Board Changes, Effective February 20, 2026	CI
02-17	Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
02-10	Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026.	CI
02-10	9,200,029 Common Stock of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026.	CI
02-05	Propanc Biopharma, Inc. Unveils Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market	CI
01-20	Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia	CI
01-15	Propanc Biopharma, Inc. Announces the Latest Update on Pancreatic Cancer Research	CI

Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Employees

Sector

Biotechnology & Medical Research

More about the company